Shoulder Innovations (NYSE:SI) Major Shareholder Healthcare Holding B.V. Gilde Sells 7,338 Shares of Stock

Shoulder Innovations, Inc. (NYSE:SI) major shareholder Healthcare Holding B.V. Gilde sold 7,338 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $22.64, for a total value of $166,132.32. Following the completion of the transaction, the insider directly owned 2,214,302 shares in the company, valued at $50,131,797.28. The trade was a 0.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Healthcare Holding B.V. Gilde also recently made the following trade(s):

• On Thursday, August 6th, Healthcare Holding B.V. Gilde sold 2,095 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.60, for a total value of $47,347.00.
• On Tuesday, August 4th, Healthcare Holding B.V. Gilde sold 99,812 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.77, for a total value of $2,272,719.24.
• On Monday, August 3rd, Healthcare Holding B.V. Gilde sold 10,751 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.71, for a total value of $244,155.21.
• On Friday, July 31st, Healthcare Holding B.V. Gilde sold 20,034 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.73, for a total value of $455,372.82.
• On Thursday, July 30th, Healthcare Holding B.V. Gilde sold 28,245 shares of Shoulder Innovations stock. The shares were sold at an average price of $23.36, for a total value of $659,803.20.

Shoulder Innovations Stock Down 8.4%

Shares of NYSE SI opened at $20.54 on Friday. Shoulder Innovations, Inc. has a 12-month low of $10.92 and a 12-month high of $24.59. The firm’s 50-day simple moving average is $19.91 and its 200 day simple moving average is $16.07. The company has a quick ratio of 10.04, a current ratio of 11.81 and a debt-to-equity ratio of 0.11. The company has a market cap of $426.06 million and a price-to-earnings ratio of -10.70.

Shoulder Innovations (NYSE:SI) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.03. Shoulder Innovations had a negative net margin of 58.33% and a negative return on equity of 22.93%. The firm had revenue of $16.71 million during the quarter. On average, research analysts expect that Shoulder Innovations, Inc. will post -1.67 earnings per share for the current fiscal year.

Institutional Trading of Shoulder Innovations

A number of institutional investors have recently bought and sold shares of SI. Bank of America Corp DE lifted its stake in shares of Shoulder Innovations by 43.7% in the 1st quarter. Bank of America Corp DE now owns 26,983 shares of the company’s stock valued at $392,000 after purchasing an additional 8,205 shares during the period. Royal Bank of Canada boosted its position in shares of Shoulder Innovations by 7,046.3% in the 1st quarter. Royal Bank of Canada now owns 53,883 shares of the company’s stock worth $783,000 after purchasing an additional 53,129 shares during the last quarter. KCM Capital Inc acquired a new stake in shares of Shoulder Innovations during the first quarter worth $509,000. Roubaix Capital LLC increased its holdings in Shoulder Innovations by 61.9% in the first quarter. Roubaix Capital LLC now owns 257,121 shares of the company’s stock valued at $3,736,000 after purchasing an additional 98,305 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Shoulder Innovations in the first quarter valued at about $252,000.

Key Stories Impacting Shoulder Innovations

Here are the key news stories impacting Shoulder Innovations this week:

• Positive Sentiment: Analysts raised their targets: Piper Sandler reaffirmed its “overweight” rating and lifted its price target from $19 to $25, while BTIG Research raised its target from $24 to $26 and initiated a “buy” rating. These targets imply meaningful upside and may support investor sentiment. Benzinga analyst rating updates
• Positive Sentiment: Revenue growth remained strong: Second-quarter revenue increased approximately 56% year over year to $17.2 million, slightly exceeding estimates. Gross profit rose about 60%, indicating continued demand and improving product economics. Shoulder Innovations Q2 2026 earnings summary
• Positive Sentiment: Full-year guidance was raised: SI forecast fiscal-year revenue of $67 million to $69 million, broadly in line with the roughly $67.1 million consensus estimate. Management also highlighted 60% first-half revenue growth. Shoulder Innovations raises full-year outlook
• Neutral Sentiment: Liquidity appears adequate but is declining: The company ended the quarter with $24.5 million in cash and used $7.4 million in operating activities and $2.2 million in capital expenditures. Investors will likely monitor whether revenue growth can lead to improved cash generation.
• Negative Sentiment: Profitability remains a concern: SI reported an operating loss of about $10 million, a net loss of approximately $10.2 million, and diluted EPS near negative $0.49, missing some estimates. The company remains deeply unprofitable, increasing valuation sensitivity. Shoulder Innovations quarterly results
• Negative Sentiment: Major-holder selling may weigh on sentiment: Gilde Healthcare sold more than 110,000 shares in early August for roughly $2.5 million. Although it retains a substantial stake, the sales can raise concerns about near-term supply and insider conviction. Gilde Healthcare insider sale

Analyst Upgrades and Downgrades

SI has been the topic of several research reports. Weiss Ratings raised Shoulder Innovations from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday. Piper Sandler reissued an “overweight” rating and issued a $25.00 target price (up from $19.00) on shares of Shoulder Innovations in a research note on Friday. BTIG Research boosted their target price on Shoulder Innovations from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday. Finally, UBS Group assumed coverage on Shoulder Innovations in a research note on Tuesday, July 28th. They set a “buy” rating and a $27.00 price target on the stock. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $23.33.

About Shoulder Innovations

Shoulder Innovations (NYSE:SI) is a medical device company focused on the design, development and commercialization of shoulder implant systems and related surgical instruments for orthopedic surgery. The company’s product portfolio includes modular shoulder prostheses, humeral and glenoid components, and instrumentation kits designed to facilitate both primary and revision shoulder arthroplasty procedures. Emphasizing a patient-centric approach, Shoulder Innovations works to offer implant solutions that aim to restore mobility and reduce post-operative complications.

In addition to its core implant offerings, Shoulder Innovations provides comprehensive clinical support and training programs for surgeons and operating room teams.